ERBB2 and breast cancer: Previous studies with 64Cu-DOTA-Trastuzumab [6, 18] evaluated breast cancer patients with only HER2-positive tumors; however, despite the limitation of the small sample number, our study included both patients with HER2-positive and negative tumors.